Immutep Limited - American Depositary Shares (IMMP) closed at $3.00 on November 3, 2026, down 2.4% from the previous close, on volume of 11,956 shares (30-day average 73,563).
Data as of November 3, 2026.
3-Nov-2026
Immutep Quarterly Activities Report Q1 FY27
Globe Newswire (Thu, 29-Oct 8:00 AM ET)
Immutep Receives A$2.16 million French R&D Tax Incentive
Globe Newswire (Wed, 28-Oct 8:00 AM ET)
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
Globe Newswire (Fri, 23-Oct 8:00 AM ET)
Globe Newswire (Mon, 19-Oct 8:00 AM ET)
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
Globe Newswire (Wed, 14-Oct 8:00 AM ET)
Immutep regains Nasdaq bid-price compliance after 10-day streak above $1 and an ADS ratio change
Market Chameleon (Tue, 13-Oct 7:45 AM ET)
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Tue, 13-Oct 8:00 AM ET)
Immutep Receives ~A$0.86 Million R&D Tax Incentive
Globe Newswire (Wed, 30-Sep 8:00 AM ET)
Change to American Depositary Share Ratio
Globe Newswire (Mon, 21-Sep 8:00 AM ET)
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa ('efti')
Globe Newswire (Fri, 11-Sep 8:00 AM ET)
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Immutep Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol IMMP.
As of November 3, 2026, IMMP stock price declined to $2.99 with 11,956 million shares trading.
IMMP has a beta of 5.10, meaning it tends to be more sensitive to market movements. IMMP has a correlation of 0.09 to the broad based SPY ETF.
IMMP has a market cap of $22.07 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, IMMP traded as high as $70.60 and as low as $2.99.
The top ETF exchange traded funds that IMMP belongs to (by Net Assets): IBB.
IMMP has underperformed the market in the last year with a price return of -92.1% while the SPY ETF gained +11.7%. IMMP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -60.8% and -5.5%, respectively, while the SPY returned +1.2% and -1.6%, respectively.
IMMP support price is $2.89 and resistance is $3.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMMP shares will trade within this expected range on the day.
